1. Home
  2. KRMD vs TVGN Comparison

KRMD vs TVGN Comparison

Compare KRMD & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KORU Medical Systems Inc. (DE)

KRMD

KORU Medical Systems Inc. (DE)

SELL

Current Price

$3.48

Market Cap

146.4M

Sector

Health Care

ML Signal

SELL

Logo Tevogen Bio Holdings Inc.

TVGN

Tevogen Bio Holdings Inc.

SELL

Current Price

$5.31

Market Cap

21.3M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
KRMD
TVGN
Founded
1980
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
146.4M
21.3M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
KRMD
TVGN
Price
$3.48
$5.31
Analyst Decision
Buy
Analyst Count
4
0
Target Price
★ $6.13
N/A
AVG Volume (30 Days)
★ 177.7K
7.6K
Earning Date
11-10-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 53.85
N/A
EPS
★ N/A
N/A
Revenue
★ $41,127,366.00
N/A
Revenue This Year
$17.24
N/A
Revenue Next Year
$16.13
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 22.23
N/A
52 Week Low
$2.86
$0.14
52 Week High
$6.61
$24.91

Technical Indicators

Market Signals
Indicator
KRMD
TVGN
Relative Strength Index (RSI) 55.10 44.82
Support Level $3.00 $5.01
Resistance Level $4.27 $7.33
Average True Range (ATR) 0.26 0.43
MACD 0.05 0.03
Stochastic Oscillator 48.26 41.40

Price Performance

Historical Comparison
KRMD
TVGN

About KRMD KORU Medical Systems Inc. (DE)

KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.

About TVGN Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.

Share on Social Networks: